Table 2.

Proportion of Patients Free from Severe Exacerbations Before and During Benralizumab Treatment in Naïve, Bio-Experienced, Omalizumab, and Mepolizumab Groups

	Naïve (N=117, 110, 86)	Bio-Experienced (N=37, 35, 27)	Omalizumab (N=20, 20, 17)	Mepolizumab (N=17, 15, 10)
Patients without severe exacerbations at index date, N (%)	78 (66.7)	19 (51.4)	9 (45.0)	10 (58.8)
Patients without severe exacerbations at 48 weeks, N (%)	106 (96.4)	30 (85.7)	16 (80.0)	14 (93.3)
Patients without severe exacerbations at 96 weeks, N (%)	84 (97.7)	23 (85.2)	14 (82.4)	9 (90.0)

Notes: Data were collected at index date and at 48 and 96 weeks of benralizumab treatment; data are expressed as N (%).

Abbreviation: N, number of patients.